AgomAb Therapeutics NV American Depositary Shares (AGMB) is a publicly traded the market company. As of May 21, 2026, AGMB trades at $10.69 with a market cap of $520.06M and a P/E ratio of 0.00. AGMB moved +0.76% today. Year to date, AGMB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $9.00 to $17.45. Analyst consensus is strong buy with an average price target of $32.00. Rallies surfaces AGMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Agomab Raises $208M IPO, Holds €116.5M Cash and Eyes H2 Trials: Agomab ended 2025 with €116.5 million in cash and raised $208 million in a February IPO, extending its cash runway into H1 2029. The company will initiate Phase 2b ontunisertib in Crohn’s fibrostenosing disease and Phase 2 AGMB-447 in IPF, with topline data expected in H2 2026.
| Metric | Value |
|---|---|
| Price | $10.69 |
| Market Cap | $520.06M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.45 |
| 52-Week Low | $9.00 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover AGMB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.00.